- ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF
-
A compound of Formula (I) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: Formula (I) wherein R1 and Y are as defined herein.
- -
-
Page/Page column 78-79
(2020/04/25)
-
- PHENOTHIAZINE DERIVATIVES AND USES THEREOF
-
The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).
- -
-
Paragraph 00365-00366
(2019/10/29)
-
- Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists
-
Mineralocorticoid receptor (MR) antagonists continue to be a prevalent area of research in the pharmaceutical industry. Herein we report the discovery of various spirooxindole and dibenzoxazepine constructs as potent MR antagonists. SAR analysis of our spirooxindole hit led to highly potent compounds containing polar solubilizing groups, which interact with the helix-11 region of the MR ligand binding domain (LBD). Various dibenzoxazepine moieties were also prepared in an effort to replace a known dibenzoxepane system which interacts with the hydrophobic region of the MR LBD. In addition, an X-ray crystal structure was obtained from a highly potent compound which was shown to exhibit both partial agonist and antagonist modes of action against MR.
- Lotesta, Stephen D.,Marcus, Andrew P.,Zheng, Yajun,Leftheris, Katerina,Noto, Paul B.,Meng, Shi,Kandpal, Geeta,Chen, Guozhou,Zhou, Jing,McKeever, Brian,Bukhtiyarov, Yuri,Zhao, Yi,Lala, Deepak S.,Singh, Suresh B.,McGeehan, Gerard M.
-
supporting information
p. 1384 - 1391
(2016/03/01)
-
- Anesthetic compounds and related methods of use
-
Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.
- -
-
Page/Page column 67
(2015/11/09)
-
- ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE
-
Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.
- -
-
Paragraph 00206
(2013/07/25)
-
- Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists
-
Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1 homology models derived from the X-ray structure of the β2-adrenergic receptor, including extracellular loops, were developed and used to guide the design.
- Sasmal, Sanjita,Balaji, Gade,Kanna Reddy, Hariprasada R.,Balasubrahmanyam,Srinivas, Gujjary,Kyasa, Shivakumar,Sasmal, Pradip K.,Khanna, Ish,Talwar, Rashmi,Suresh,Jadhav, Vikram P.,Muzeeb, Syed,Shashikumar, Dhanya,Harinder Reddy,Sebastian,Frimurer, Thomas M.,Rist, ?ystein,Elster, Lisbeth,H?gberg, Thomas
-
scheme or table
p. 3157 - 3162
(2012/06/04)
-
- PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF
-
A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.
- -
-
Page/Page column 224
(2010/08/04)
-
- DIAZASPIRODECANE OREXIN RECEPTOR ANTAGONISTS
-
The present invention is directed to diazaspirodecane compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
- -
-
Page/Page column 27-28
(2008/06/13)
-
- Oxazolones as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1
-
2,5,5-Trisubstituted oxazolones were identified as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The synthesis, structure-activity relationship and metabolic stability of these compounds are presented.
- Sutin, Lori,Andersson, Soeren,Bergquist, Lars,Castro, Victor M.,Danielsson, Eva,James, Stephen,Henriksson, Martin,Johansson, Lars,Kaiser, Christina,Flyren, Katarina,Williams, Meredith
-
p. 4837 - 4840
(2008/02/11)
-
- Spiro-rifamycin derivatives targeting RNA polymerase
-
Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.
- -
-
Page/Page column 17
(2008/06/13)
-
- The CSIC [carbanion mediated sulfonate (sulfonamido) intramolecular cyclization] reaction: Scope and limitations
-
The CSIC (Carbanion-mediated Sulfonate-Sulfonamide-Intramolecular Cyclization) reaction has been extended to new carbonyl containing substrates, showing the scope and limitations of this process. Suitable derivatives of ketones (e.g acetophenone (1)), β-keto esters (e.g ethyl acetoacetate (4)), γ-keto esters (e.g ethyl 2-oxocyclohexaneacetate (5) and ethyl levulinate (6)) proved reluctant to undergo this protocol. Cyclopropyl methyl ketone (2) gave the heterocycle (3), only in the 'sulfonamide' synthetic sequence of the CSIC reaction. Cyclic azaketones (e.g tropinone (7)) fated also, but 4-piperidones (9, 10) afforded the novel 3,8- disubstituted 4-amino-8-aza-1-oxa-2-thiaspiro[4.5]dec-3-ene 2,2-dioxide (12, 15a-c) and 8-substituted 4-amino-1,8-diaza-2-thiaspiro[4.5]dec-3-ene 2,2- dioxide (18a, 18b, 21a, 21b) ring systems; the former compounds are the first examples of such ring systems substituted at the 3-position, whereas the latter represent the first ever representatives of spiro fused systems containing the 4-amino-2,3-dihydroisothiazole 1,1-dioxide moiety. Base promoted (NaH or DBU) cyclization of precursors 11b, 14a-c, 17b, 17c and 20 give the final adducts in good overall yield. Finally, we were unsuccessful with some conveniently functionalized anthranilonitrile derivatives (8a-d), in an attempt to extend the CSIC reaction to β-aminonitriles. As a result of these studies the substrate dependent reactivity in the CSIC reaction has been analyzed in depth and some restrictions and limitations have been observed and discussed.
- Marco, Jose L.,Ingate,Chinchon
-
p. 7625 - 7644
(2007/10/03)
-
- 1,3,8-TRIAZA- AND 3,8-DIAZA-1-OXASPIRO[4,5] DECANE DERIVATIVES
-
Heterocyclic compounds of Formula I: STR1 in which n is 2, 3, 4, 5 or 6; t is 1, 2, 3 or 4; u is 0 or 1 (provided that t is not 1 when u is 0); X is O or N(R 4); Y and Z are independently C(O), C(S) or CH 2 (provided that Y and Z are not both CH 2); R 1, R. sup.2, R 3, and R 4 are as defined in the specification; and their pharmaceutically acceptable salts and N-oxides, formulations containing them, their uses as therapeutic agents, and their synthesis.
- -
-
-
- Synthesis and Structure-Activity Studies of a Series of Spirooxazolidine-2,4-diones: 4-Oxa Analogues of the Muscarinic Agonist 2-Ethyl-8-methyl-2,8-diazaspirodecane-1,3-dione
-
A series of spirooxazolidine-2,4-dione derivatives related to the putative M1 agonist 2-ethyl-8-methyl-2,8-diazaspirodecane-1,3-dione (RS86; 1) were synthesized.The compounds were evaluated as cholinergic agents in in vitro binding assays and in in vivo pharmacological tests including antiamnesic effects using scopolamine-treated mice, hypothermia, and salivation in mice.Four compounds (5a,c,f and 17a) exhibited affinity for cortical M1 receptors and reversed scopolamine-induced impairment of mouse passive avoidance tasks, as did 1.Among these compounds only 5a exhibited M1-receptor stimulating activity in pithed rats.Structural requirements for muscarinic activity in this series of spirooxazolidine-2,4-dione derivatives were as strict as those reported for spirocuccinimide derivatives including 1.The antiamnesic dose of 3-ethyl-8-methyl-1-oxo-3,8-diazaspirodecane-2,4-dione (5a) was 2 orders of magnitude lower than the doses inducing hypothermia and salivation, in contrast to 1 for which the former dose was only 5-10-fold lower than the latter.These results suggest that the 8-azaspirodecane skeleton represents a useful template for designing new muscarinic agonists as antidementia drugs.
- Tsukamoto, Shin-ichi,Ichihara, Masato,Wanibuchi, Fumikazu,Usuda, Shinji,Hidaka, Kazuyuki,et al.
-
p. 2292 - 2299
(2007/10/02)
-